News · By Jacob Teague · · Updated

An FDA panel voted on six peptides. That is not approval.

A committee can recommend. The agency still has to write a rule. The vote itself did not change the legal status of these peptides.

Update, November 11, 2026. On October 30, 2026, HHS published a draft enforcement discretion policy for compounding certain peptides. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds with a peptide on its list while the 503A Bulks List is developed through rulemaking. Law-firm summaries of the policy list the same six peptides the committee backed (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500) and ten conditions, including a valid patient-specific prescription. Outsourcing facilities are not covered. The policy does not approve any peptide, does not add any peptide to the Bulks List, and is not binding. HHS says it may revisit it if a safety or quality problem arises. Comments were due November 13, 2026. None of these peptides is an FDA-approved drug.

FDA’s Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026. It recommended six peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. It voted against emideltide (also called DSIP).

On day 1 (July 23), BPC-157, KPV, and TB-500 each went 8–6 with 1 abstention. MOTS-c went 7–5 with 2 abstentions. Free base and acetate were voted separately on several of these.

FDA scientific staff had recommended against including all seven, citing short, small studies and insufficient safety and effectiveness data. BPC-157 was evaluated for ulcerative colitis. TB-500 was evaluated for wound healing.

A PCAC recommendation is not FDA approval and does not put a substance on the 503A Bulks List. FDA would still need notice-and-comment rulemaking — a proposed rule, comment, and a final rule. FDA is not required to follow the committee. None of these peptides is an FDA-approved drug.

Related: What people mean by BPC-157 and TB-500.

Citations

Peptide Vault is a personal log and research library. Not medical advice, not a pharmacy, not a shop. We do not tell you what to take or where to get it. No dosing. No where-to-buy. No mix tutorials. No heal/optimize claims.

Optional

Peptide brief

Weekly. What changed. What isn’t approved.

Optional. Weekly if we send it. Not a protocol.